Béata Juzyna
UniCancer Group(FR)
Publications by Year
Research Areas
Colorectal and Anal Carcinomas, Colorectal Cancer Surgical Treatments, Pancreatic and Hepatic Oncology Research, Health Systems, Economic Evaluations, Quality of Life, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer(2018)2,781 cited
- → Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial(2021)1,199 cited
- → Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial(2021)758 cited
- → Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial(2014)436 cited
- → Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer(2012)428 cited
- → Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.(2020)177 cited
- → Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.(2017)110 cited
- → Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer(2017)105 cited
- → Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial(2013)89 cited
- → Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial(2015)81 cited